Effects of IgLON5 Antibodies on Neuronal Cytoskeleton: A Link between Autoimmunity and Neurodegeneration.


Journal

Annals of neurology
ISSN: 1531-8249
Titre abrégé: Ann Neurol
Pays: United States
ID NLM: 7707449

Informations de publication

Date de publication:
11 2020
Historique:
received: 08 05 2020
revised: 28 07 2020
accepted: 29 07 2020
pubmed: 3 8 2020
medline: 15 12 2020
entrez: 3 8 2020
Statut: ppublish

Résumé

Anti-IgLON5 disease is a neurological disorder characterized by autoantibodies against IgLON5 and pathological evidence of neuronal-specific tau accumulation. Here, we report that patients' IgLON5 IgG, but not other cell-surface antibodies, disrupt the cytoskeletal organization in cultured rat hippocampal neurons, resulting in dystrophic neurites and axonal swelling. Adsorption of IgLON5 IgG with HEK293 cells expressing IgLON5 abrogated the indicated cytoskeletal changes. These findings, along with an increase of levels of neurofilaments in patients' cerebrospinal fluid, suggest that IgLON5 IgG, unlike other cell-surface antibodies, disrupts neuronal cytoskeleton maintenance, providing a link between autoimmunity and neurodegeneration. ANN NEUROL 2020;88:1023-1027.

Identifiants

pubmed: 32740999
doi: 10.1002/ana.25857
doi:

Substances chimiques

Antibodies 0
Cell Adhesion Molecules, Neuronal 0
IgLON5 protein, human 0
Immunoglobulin G 0
Neurofilament Proteins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1023-1027

Informations de copyright

© 2020 American Neurological Association.

Références

Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol 2014;13:575-586.
Gaig C, Ercilla G, Daura X, et al. HLA and microtubule-associated protein tau H1 haplotype associations in anti-IgLON5 disease. Neurol Neuroimmunol Neuroinflamm 2019;6:e605.
Sabater L, Planagumà J, Dalmau J, Graus F. Cellular investigations with human antibodies associated with the anti-IgLON5 syndrome. J Neuroinflammation 2016;13:226.
Gaig C, Graus F, Compta Y, et al. Clinical manifestations of the anti-IgLON5 disease. Neurology 2017;88:1736-1743.
Gelpi E, Höftberger R, Graus F, et al. Neuropathological criteria of anti-IgLON5-related tauopathy. Acta Neuropathol 2016;132:531-543.
Honorat JA, Komorowski L, Josephs KA, et al. IgLON5 antibody: neurological accompaniments and outcomes in 20 patients. Neurol Neuroimmunol NeuroInflamm 2017;4:e385.
Erro ME, Sabater L, Martínez L, et al. Anti-IGLON5 disease a new case without neuropathologic evidence of brainstem tauopathy. Neurol Neuroimmunol NeuroInflamm 2019; 11;7:e651.
Buchhalter JR, Dichter MA. Electrophysiological comparison of pyramidal and stellate nonpyramidal neurons in dissociated cell culture of rat hippocampus. Brain Res Bull 1991;26:333-338.
Cui Y, Jin X, Choi DJ, et al. Axonal degeneration in an in vitro model of ischemic white matter injury. Neurobiol Dis 2020;134:104672.
Kim MJ, Oh SJ, Park SH, et al. Neuronal loss in primary long-term cortical culture involves neurodegeneration-like cell death via calpain and p35 processing, but not developmental apoptosis or aging. Exp Mol Med 2007;39:14-26.
Stokin GB, Lillo C, Falzone TL, et al. Axonopathy and transport deficits early in the pathogenesis of Alzheimer's diseases. Science 2005;307:1282-1288.
Bridel C, Van Wieringen WN, Zetterberg H, et al. Diagnostic value of cerebrospinal fluid Neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 2019;76:1035-1048.
Tan RPA, Leshchyns'Ka I, Sytnyk V. Glycosylphosphatidylinositol-anchored immunoglobulin superfamily cell adhesion molecules and their role in neuronal development and synapse regulation. Front Mol Neurosci 2017;10:378.
Head BP, Patel HH, Insel PA. Interaction of membrane/lipid rafts with the cytoskeleton: impact on signaling and function: membrane/lipid rafts, mediators of cytoskeletal arrangement and cell signaling. Biochim Biophys Acta - Biomembr 2014;1838:532-545.
Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840-851.
Dale RC, Tantsis EM, Merheb V, et al. Antibodies to MOG have a demyelination phenotype and affect oligodendrocyte cytoskeleton. Neurol Neuroimmunol Neuroinflamm 2014;1:e12.

Auteurs

Jon Landa (J)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Carles Gaig (C)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.

Jesús Plagumà (J)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Albert Saiz (A)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.

Ana Antonell (A)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Raquel Sanchez-Valle (R)

Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain.

Josep Dalmau (J)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.
Service of Neurology, Hospital Clinic de Barcelona, Barcelona, Spain.
Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.

Francesc Graus (F)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Lidia Sabater (L)

Neuroimmunology Program, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Universitat de Barcelona, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH